Global Adalimumab Drugs Market Size (2024 - 2029)

Adalimumab Drugs Market Analysis

The Global Adalimumab Drugs Market is projected to register a CAGR of 5.1% during the forecast period (2022-2027).

COVID-19 has put infectious-disease antibodies back in the spotlight. As per an article titled 'Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients' published in March 2022, patients with Immunomodulatory drugs (IMiDs) treated with infliximab and adalimumab have attenuated serological responses to SARS-CoV-2 infection with lower seroprevalence and antibody reactivity when compared to vedolizumab-treated patients. Therefore, the drug is expected to have a significant impact on COVID patients during the pandemic and affect the growth of the market respectively. As per another article titled 'COVID antibody drugs have saved lives - so why aren't they more popular?' published in June 2022, Adalimumab, which is considered the top-selling drug in the pandemic, soothes rheumatoid arthritis and other autoimmune conditions by mopping up the inflammatory protein TNF-α. Pembrolizumab, on track to overtake adalimumab's sales, binds to a protein on the immune system's T cells to unleash the body's defenses against cancers. This is also expected to have a significant impact on market growth. In 2021, the Food and Drug Administration (FDA) approved its 100th monoclonal antibody, and these drugs collectively reap around USD 150 billion in sales worldwide every year.

Biopharmaceutical medicines have transformed the way that a wide range of disorders are treated, and they are being utilized more often in almost all areas of medicine. Due to the enormous demand for these medications, the market for biopharmaceuticals has grown significantly more quickly than the overall pharmaceutical market in recent years and is thought to have a significant amount of potential for further dynamic growth. Single-use systems represent the future in biopharmaceutical processing of therapeutic drugs with significant advantages over traditional reusable stainless-steel systems and partly disposable systems. As per the Global RA Network-2022, arthritis affects more than 350 million people and became a leading cause of disability which trigger market growth. The prevalence of arthritis, growing acceptance of biopharmaceuticals, and the presence of well-defined regulatory guidelines in developed economies are among the key trends expected to trigger market growth.

Increasing launches of novel biosimilar and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, in May 2022, Biocon Biologics Ltd. and Viatris Inc. announced that Abevmy is available in Canada. Abevmy, co-developed by Biocon Biologics and Viatris, is biosimilar to Roche's Avastin and has been approved by Health Canada across four oncology indications. Similarly, in February 2022, Dr. Reddy's Laboratories launches a generic drug in the United States market. Additionally, in January 2022, Biocon reported strong growth in its biosimilars business and the launch of the first interchangeable biosimilar glargine in the US will drive further growth in this segment. Similarly, ABP 501, a novel Adalimumab biosimilar by Amgen, is awaiting approval by 2020. Recently approved biologics such as Hyrimoz (adalimumab-adaz) by Novartis and ABRILADA (adalimumab-AFB) by Pfizer is poised to have strong market penetration due to the presence of a favorable reimbursement scenario.

Growing patient awareness regarding arthritis disorders and the influx of new biopharmaceuticals in the global arena are projected to increase the adoption of adalimumab drugs. For instance, as per an article titled 'The Prevalence and Statistics of Arthritis' published in February 2022, the prevalence of arthritis in the United States has increased, and it will continue to climb as the baby boomer generation ages. More than 22% of American adults (over 52.5 million people) have arthritis or another rheumatic condition diagnosed by doctors. By 2030, the number of people with arthritis (adults 18 years and older) is expected to rise to 67 million. Similarly, according to the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population, data published in October 2021, about 1 in 4 US adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. Arthritis prevalence increases with age. Therefore, the aging population can also be a driving factor for the market. According to World Health Organization (WHO) key facts updated in October 2021, By 2020, the number of people aged 60 years and older will outnumber children younger than 5 years and between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Thus the increasing age and the increasing prevalence and awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth and accelerate the market.

However, side effects associated with this drug such as vomiting, nausea, internal bleeding, anaphylaxis, and respiratory tract infections may restrain the growth of the market.

Adalimumab Drugs Industry Segmentation

As per the scope of the report, Adalimumab, which is a patent product of Abbott, is a medication used for the treatment of ulcerative colitis, psoriatic arthritis, and rheumatoid arthritis. It is also known as HUMIRA, intended to inject subcutaneously. It can help in preventing conditions causing damage to the body. Adalimumab drug market is segmented by disease type and geography. The Adalimumab Drugs Market is Segmented By Disease Type (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Others) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.